HypertensionPhase 1/2NCT02104375
L-citrulline Supplementation, Cold Exposure, & Post-Exercise Muscle Ischemia
A Phase 1/2 study testing L-citrulline in people with Hypertension, run by Florida State University at 1 site in United States.
Trial summary
Cardiovascular disease (CVD) continues to be the major cause of morbidity and mortality in western countries. It has been shown that CVD events are known to be higher in the winter than in the summer. Read more about this study
- Who is it for?
- Ages 18 to 35 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Hypertension
- What is being tested?
- L-citrulline
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 16 participants
- Where
- 1 siteUnited States
- Study dates
- Mar 2013to Dec 2014
- Phase
- Phase 1/2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 35 years
- Men only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Men
- Blood pressure lower than 140/90mmHg
- Age 18 to 35 years
- BMI 25-39 kg/m2
Who cannot join
- Blood Pressure >160/100 mmHg
- Asthma
- Glaucoma
- Herpes simplex
- Uncontrolled diabetes
- Neurological disease
Show all 18Show fewer
- Cardiovascular disease
- Inflammatory disease
- Kidney disease
- Hormone replacement therapy (HRT)
- Amino acid/vitamin supplementation\
- Corticosteroids or non-steroidal anti-inflammatory drugs
- Any drug known to affect BP or heart rate
- Glycemic control drugs
- Lipids reducing drugs
- Participants should not consume > 12 alcoholic drink/week
- Smokers
- Regular Exercisers (>1.5 hour/week).
Trial locations and contacts
1 site in 1 country.
United States1 site
FSU College of Human Sciences
Tallahassee, Florida, 32306
About this study
Official title: The Effects of L-Citrulline Supplementation on Vascular and Cardiac Autonomic Responses to Cold Pressor Test Concurrent With Postexercise Muscle Ischemia
Cardiovascular disease (CVD) continues to be the major cause of morbidity and mortality in western countries. It has been shown that CVD events are known to be higher in the winter than in the summer. Low environmental temperatures may induce increased cardiovascular stress resulting in cold-induced hypertension (CIH), the leading risk factor for CVD events. Similar to whole-body cold exposure, the cold pressor test (CPT), an external local cold stimulus, has been used for evaluation of cardiovascular and hemodynamic reactivity to sympathetic stimulation. It has been shown that brachial blood pressure (BP), pressure pulse wave reflection, aortic BP, heart rate (HR), and arterial stiffness are increased during CPT. However, the physiologic mechanisms for the cardiovascular complications related to low temperatures are not completely clear.
Isometric-handgrip (IHG) exercise has been used as a tool for assessing cardiovascular autonomic control by a maneuver defined as post-exercise muscle ischemia (PEMI). PEMI induces exercise pressor reflex (metaboreflex) by trapping metabolites in the previous active muscle at the cessation of exercise. During PEMI, the accumulation of contraction-derived metabolites induces sympathetic mediated vascular stimulation and an increased BP, whereas the HR fully recovers. This suggests that the fall in HR is evoked by an increase in parasympathetic activity which overpowers the sympathetic activation. Implication of IHG exercise followed by PEMI provides important clinical information because impaired autonomic and cardiovascular functions are associated with cardiovascular events.
Recently, oral supplementation with the amino acid L-citrulline (L-cit) has been proposed as a possible adjunct treatment for hypertension and arterial stiffness. L-cit is known to enhance the bioavailability of L-arginine (L-arg), the endothelial substrate for nitric oxide (NO) production. Cold exposure might include a temperature-dependent inhibition of endothelial NO synthase (eNOS), the enzyme that produces NO from the amino acid L-arg and may trigger various types of CVD. It has been shown that L-cit supplementation has effectively attenuated the CIH response during cold pressor test. Thus, L-cit supplementation may be effective to reduce the cardiovascular responses associated with cold exposure and the exercise pressor reflex imposed by PEMI. Therefore, the proposed study is important for the following reasons: (1) the results of his study will add to our understanding regarding the cardiovascular and autonomic mechanisms associated with exercise and cold exposure; (2) the results of this study will contribute to the development of an adjunct therapy for the prevention of cardiovascular adverse events that are particularly increased during stress such as cold exposure and exercise.
Read the detailed description
Specific Aims
AIM 1: To determine the acute effects of the exercise pressor response imposed by PEMI with and without CPT on hemodynamics and cardiac autonomic regulation in health overweight/obese men.
AIM 2: To examine the effects of a 14-day course of L-cit supplementation on arterial stiffness, aortic hemodynamics, and autonomic regulation at rest and during conditions characterized by increased sympathetic activity (IHG, PEMI, and PEMI concurrent with CPT).
Research Hypotheses
Hypothesis 1: There will be greater increases in peripheral and central BP, arterial stiffness, wave reflection, and cardiac sympathetic activity during PEMI concurrent with CPT than during PEMI alone.
Hypothesis 2: 14 days of L-cit supplementation will attenuate peripheral and central BP, wave reflection, arterial stiffness, and cardiac sympathetic activity responses during IHG exercise, PEMI, and PEMI concurrent with CPT compared with placebo (PL) supplementation.
Description of the study
A total of twenty male young adults (18-35 years) with overweight or obesity [body mass index (BMI) >25 and <40 kg/m2] will be enrolled in this study. All of the subjects will be nonsmokers, no L-cit or L-arg users or regular exercisers (defined as more than 120 min per week) at least 6 months before the study begins. Subjects will be asked to maintain their diet and exercise habits during the study period.
Study design:
After completion of initial screening, cardiovascular and autonomic function of eligible subjects will be evaluated in a quiet temperature-controlled room (22-24°C). After baseline measurement, in a cross-over design fashion, subjects will be randomized to either Placebo group (Maltodextrin) or L-citrulline group for the first 14 days of the study that will be followed by a 14 day washout period and then will be crossed over to their next treatment. Cardiovascular function will be evaluated at baseline and after 14 days of the first and the second treatment. Measurements will be conducted in the morning after at least 8 hours of an overnight fast in order to avoid potential diurnal variations in BP and vascular reactivity.
- Conditions
- Hypertension
- Being tested
- L-citrulline
- Keywords
- wave reflection, augmentation Index, heart rate variability, arterial stiffness
- Medical subject headings
- Hypertension
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
L-citrullineDietary supplement
Also called 2 weeks of L-citrulline supplementation (6g/day).
2 weeks of L-citrulline supplementation (6g/day).
| Study group | Role | What they receive |
|---|---|---|
| L-citrulline | Experimental | L-citrulline (6 g/day for 2 weeks) Receives: Dietary Supplement: L-citrulline |
| Maltodextrin | Placebo comparator | 6g/day of placebo (maltodextrin) Receives: Dietary Supplement: L-citrulline |
What is being measured
The primary outcome is the main question the study is designed to answer.
Blood Pressure
By measuring brachial and central (aortic and carotid) BP at rest and during physiological stress (cold pressor test, post-exercise muscle ischemia, and handgrip test)
Measured: 6 weeks
Secondary outcomes (1)
Arterial Stiffness
By measuring brachial-ankle pulse wave velocity at rest and during physiological stress (cold pressor test, post-exercise muscle ischemia, and handgrip test)
Measured: 6 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Apr 2014 (estimated)
- Study startMar 2013
- Primary completionDec 2013
- Study completionDec 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for HypertensionStudies of the same condition, open and under way.
- More trials run by Florida State UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 16 participants (actual)
Sponsor and investigators
- Lead sponsor
- Florida State University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Arturo Figueroa, Florida State University
- Investigators
- Arturo Figueroa, Principal investigator, Florida State University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02104375
- Sponsor's protocol ID
- 2013.11742
- Status last verified
- Mar 2015
- First submitted
- 2 Apr 2014
- Last updated
- 10 Mar 2015
- Results posted
- No
- Data monitoring committee
- No
Publications
Kalfon R, Campbell J, Alvarez-Alvarado S, Figueroa A. Aortic Hemodynamics and Arterial Stiffness Responses to Muscle Metaboreflex Activation With Concurrent Cold Pressor Test. Am J Hypertens. 2015 Nov;28(11):1332-8. doi: 10.1093/ajh/hpv043. Epub 2015 Apr 22.
PubMed 25904650
Study at a glance
From the registry record, last updated by the sponsor on 10 Mar 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effects of L-Citrulline Supplementation on Vascular and Cardiac Autonomic Responses to Cold Pressor Test Concurrent With Postexercise Muscle Ischemia
- ClinicalTrials.gov ID
- NCT02104375
- Acronym / sponsor ID
- 2013.11742
- Conditions
- Hypertension
- Keywords
- wave reflection, augmentation Index, heart rate variability, arterial stiffness
- Phase
- Phase 1/2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 16 participants (actual)
- Lead sponsor
- Florida State UniversityUniversity, hospital or other
- Study start
- Mar 2013
- Primary completion
- Dec 2013 (actual)
- Study completion
- Dec 2014 (actual)
- First posted
- 4 Apr 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Cardiovascular disease (CVD) continues to be the major cause of morbidity and mortality in western countries. It has been shown that CVD events are known to be higher in the winter than in the summer. Low environmental temperatures may induce increased cardiovascular stress resulting in cold-induced hypertension (CIH), the leading risk factor for CVD events. Similar to whole-body cold exposure, the cold pressor test (CPT), an external local cold stimulus, has been used for evaluation of cardiovascular and hemodynamic reactivity to sympathetic stimulation. It has been shown that brachial blood pressure (BP), pressure pulse wave reflection, aortic BP, heart rate (HR), and arterial stiffness are increased during CPT. However, the physiologic mechanisms for the cardiovascular complications related to low temperatures are not completely clear.
Isometric-handgrip (IHG) exercise has been used as a tool for assessing cardiovascular autonomic control by a maneuver defined as post-exercise muscle ischemia (PEMI). PEMI induces exercise pressor reflex (metaboreflex) by trapping metabolites in the previous active muscle at the cessation of exercise. During PEMI, the accumulation of contraction-derived metabolites induces sympathetic mediated vascular stimulation and an increased BP, whereas the HR fully recovers. This suggests that the fall in HR is evoked by an increase in parasympathetic activity which overpowers the sympathetic activation. Implication of IHG exercise followed by PEMI provides important clinical information because impaired autonomic and cardiovascular functions are associated with cardiovascular events.
Recently, oral supplementation with the amino acid L-citrulline (L-cit) has been proposed as a possible adjunct treatment for hypertension and arterial stiffness. L-cit is known to enhance the bioavailability of L-arginine (L-arg), the endothelial substrate for nitric oxide (NO) production. Cold exposure might include a temperature-dependent inhibition of endothelial NO synthase (eNOS), the enzyme that produces NO from the amino acid L-arg and may trigger various types of CVD. It has been shown that L-cit supplementation has effectively attenuated the CIH response during cold pressor test. Thus, L-cit supplementation may be effective to reduce the cardiovascular responses associated with cold exposure and the exercise pressor reflex imposed by PEMI. Therefore, the proposed study is important for the following reasons: (1) the results of his study will add to our understanding regarding the cardiovascular and autonomic mechanisms associated with exercise and cold exposure; (2) the results of this study will contribute to the development of an adjunct therapy for the prevention of cardiovascular adverse events that are particularly increased during stress such as cold exposure and exercise.
Detailed description
Specific Aims
AIM 1: To determine the acute effects of the exercise pressor response imposed by PEMI with and without CPT on hemodynamics and cardiac autonomic regulation in health overweight/obese men.
AIM 2: To examine the effects of a 14-day course of L-cit supplementation on arterial stiffness, aortic hemodynamics, and autonomic regulation at rest and during conditions characterized by increased sympathetic activity (IHG, PEMI, and PEMI concurrent with CPT).
Research Hypotheses
Hypothesis 1: There will be greater increases in peripheral and central BP, arterial stiffness, wave reflection, and cardiac sympathetic activity during PEMI concurrent with CPT than during PEMI alone.
Hypothesis 2: 14 days of L-cit supplementation will attenuate peripheral and central BP, wave reflection, arterial stiffness, and cardiac sympathetic activity responses during IHG exercise, PEMI, and PEMI concurrent with CPT compared with placebo (PL) supplementation.
Description of the study
A total of twenty male young adults (18-35 years) with overweight or obesity [body mass index (BMI) >25 and <40 kg/m2] will be enrolled in this study. All of the subjects will be nonsmokers, no L-cit or L-arg users or regular exercisers (defined as more than 120 min per week) at least 6 months before the study begins. Subjects will be asked to maintain their diet and exercise habits during the study period.
Study design:
After completion of initial screening, cardiovascular and autonomic function of eligible subjects will be evaluated in a quiet temperature-controlled room (22-24°C). After baseline measurement, in a cross-over design fashion, subjects will be randomized to either Placebo group (Maltodextrin) or L-citrulline group for the first 14 days of the study that will be followed by a 14 day washout period and then will be crossed over to their next treatment. Cardiovascular function will be evaluated at baseline and after 14 days of the first and the second treatment. Measurements will be conducted in the morning after at least 8 hours of an overnight fast in order to avoid potential diurnal variations in BP and vascular reactivity.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| L-citrulline | Experimental | Dietary Supplement: L-citrullineL-citrulline (6 g/day for 2 weeks) |
| Maltodextrin | Placebo comparator | Dietary Supplement: L-citrulline6g/day of placebo (maltodextrin) |
Who may qualify
- Ages
- 18 to 35 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Men
- Blood pressure lower than 140/90mmHg
- Age 18 to 35 years
- BMI 25-39 kg/m2
Key exclusion criteria (18 listed)
- Blood Pressure >160/100 mmHg
- Asthma
- Glaucoma
- Herpes simplex
- Uncontrolled diabetes
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| L-citrullineAlso: 2 weeks of L-citrulline supplementation (6g/day).2 weeks of L-citrulline supplementation (6g/day). | Dietary supplement | L-citrulline, Maltodextrin |
Primary outcome
Blood Pressure
Time frame: 6 weeks
By measuring brachial and central (aortic and carotid) BP at rest and during physiological stress (cold pressor test, post-exercise muscle ischemia, and handgrip test)
1 secondary outcome
Arterial Stiffness
Time frame: 6 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Mar 2015.
- Derived from this study: PubMed 25904650Kalfon R, Campbell J, Alvarez-Alvarado S, Figueroa A. Aortic Hemodynamics and Arterial Stiffness Responses to Muscle Metaboreflex Activation With Concurrent Cold Pressor Test. Am J Hypertens. 2015 Nov;28(11):1332-8. doi: 10.1093/ajh/hpv043. Epub 2015 Apr 22.
Related trials for Hypertension
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Enrolling by invitation
Testing Implementation Strategies to Support Clinic Fidelity to an Outpatient Hypertension Bundle
Pregnancy Related, Hypertension
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Arturo Figueroa principal investigator
Florida State University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1/2 study testing L-citrulline in people with Hypertension, run by Florida State University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 18 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Mar 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Blood Pressure (time frame: 6 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02104375, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Mar 2015.